Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.

By K. Rai, B. Peterson, F. Appelbaum, J. Kolitz, L. Elias, L. Shepherd, J. Hines, G. Threatte, R. Larson, B. Cheson and 1 more. New England Journal of Medicine, 2000

1,104 citations recorded by the source corpus.

Subfields: Genetics, Immunology

View Paper: https://www.semanticscholar.org/paper/0f58dbf4e927404b8e87ddcc63af6c6f8a6674e4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. T. Roberts
2. B. Chabner

Citations in the corpus

• Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). (2003, neutral): “Induction CR 33 (20-46) 15 (5-25) Induction CR PR 90 (82-98) 77 (66-89) Consolidation PR to CR* 10 (2-18) 22 (13-36) Overall CR 47 (33-61) 28 (16-40) Overall PR CR 90 (82-98) 77 (66-89)”
• Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. (2014, neutral): “Infusion-related reactions 51 (21) — 9 (4) — 67 (20) 12 (4)”
• Chemotherapy and the war on cancer (2005, background): “Montgomery's group also developed fludarabine phosphate, a purine analogue, which has become a mainstay in treatment of patients with chronic lymphocytic leukaemi”